Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
JT’s HIF-PH Inhibitor Enarodustat Non-Inferior to Nesp
Japan Tobacco’s HIF-PH inhibitor enarodustat showed non-inferiority versus the erythropoiesis-stimulating agent (ESA) Nesp (darbepoetin alfa) for the treatment of renal anemia in both non-dialysis and hemodialysis patients with chronic kidney disease. JT and its subsidiary Torii Pharmaceutical said on July…
To read the full story
Related Article
- JT’s Enarodustat 4th HIF-PH Inhibitor Filed in Japan
December 2, 2019
BUSINESS
- Japan Market Hits Record 11.8 Trillion Yen in FY2025, Keytruda Keeps Title: IQVIA
May 22, 2026
- Kissei Drops Call to Halt New Tavneos Use after Blue Letter Action
May 22, 2026
- Servier’s Voranigo Seen as Potential Standard of Care for Glioma: Expert
May 22, 2026
- Ultragenyx’s LC-FAOD Therapy Dojolvi Now Available in Japan
May 22, 2026
- SanBio Debuts Akuugo Stem Cell Therapy for Traumatic Brain Injury
May 22, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…